Asia Pacific Single Cell Analysis Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Market Size (2024) | USD 0.76 Billion |
| Market Size (2029) | USD 1.66 Billion |
| CAGR (2024 - 2029) | 16.80 % |
| Market Concentration | Medium |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Asia Pacific Single Cell Analysis Market Analysis
The Asia Pacific Single Cell Analysis Market size is estimated at USD 0.76 billion in 2024, and is expected to reach USD 1.66 billion by 2029, at a CAGR of 16.80% during the forecast period (2024-2029).
The major factors driving the market growth include technological advancements in single-cell analysis products, increasing investments in cancer research, and the rising prevalence of chronic diseases.
In the Asia-Pacific region, countries like Singapore and India are known as single-cell technology hubs, and prominent players are actively establishing their single-cell product manufacturing facilities in the country, driving regional market growth. For instance, in May 2023, Sysmex Corporation introduced its Clinical Flow Cytometry System Flow Cytometer XF-1600, Sample Preparation System PS-10, and antibody reagents in Japan, following previous launches in North America, Europe, and the Asia Pacific. Sysmex's flow cytometry portfolio, integrated with monoclonal antibody reagents, enables laboratories to fully automate the flow cytometry testing process, from sample preparation to result reporting. This comprehensive system supports the diagnosis and detailed analysis of hematological disorders, including leukemia and malignant lymphoma.
Similarly, in October 2024, Singleron Biotechnologies entered into a strategic partnership with Bioscreen, appointing them as the exclusive distributor of its advanced single-cell multi-omics solutions in India. This collaboration aims to strengthen Singleron鈥檚 presence in the single-cell analysis market in India. The partnership is expected to drive growth in the single-cell analysis market as the demand for comprehensive cellular insights continues to rise in research and clinical applications.
In addition, the increasing prevalence of cancer is driving the demand for single-cell analysis (SCA) by necessitating a deeper understanding of the molecular intricacies of tumors. SCA's ability to provide high-resolution, single-cell-level information is crucial for advancing cancer research, diagnosis, and the development of personalized treatment approaches. For instance, according to a report published by the Australian Government in August 2024, approximately 169,000 cancer cases are projected to be diagnosed in Australia in 2024. Population growth and rising cancer incidence are expected to increase to around 209,000 by 2034. Therefore, the high prevalence of cancer in the region is projected to drive the demand for SCA for early cancer detection and accurate prognosis, thereby augmenting the overall market growth.
Moreover, the strategic activities done by the prominent players in launching advanced SCA technologies in the region are also projected to drive market growth during the forecast period. For instance, in May 2023, Sysmex Corporation launched its clinical flow cytometry system, flow cytometer XF-1600, sample preparation system PS-10, antibody reagents, and other products in Japan.
Therefore, factors such as the increasing number of chronic diseases, technological advancements, and surging number of product launches are projected to drive the growth of the Asia Pacific single-cell analysis market during the forecast period. However, factors like the high cost of single-cell analysis instruments may impede market growth.
Asia Pacific Single Cell Analysis Market Trends
Next Generation Sequencing Segment is Expected to Register a Significant Share of the Market Over the Forecast Period
Next-generation sequencing (NGS) is an advanced DNA sequencing technology that enables the simultaneous sequencing of millions of DNA fragments, offering high-throughput capabilities for more efficient genetic analysis. It has become a powerful tool in genomics and is integral to the Single-Cell Analysis (SCA) market.
Significant factors such as the rising number of technological advancements, various applications of NGS in clinical and translational research, and active participation of prominent players performing multiple strategies and activities related to NGS in the region are set to drive the segment growth during the forecast period.
The ongoing advancements in NGS technologies, such as improved sequencing chemistries, faster data processing, and reduced costs, contribute to the widespread adoption of NGS in single-cell analysis. For instance, in March 2023, Illumina Inc. and GenoScreen introduced a comprehensive solution that integrates Illumina's products with the GenoScreen Deeplex Myc-TB assay, a next-generation sequencing (NGS) test designed for rapid and thorough detection of anti-TB drug resistance. This package has been launched in India to enhance the diagnostic capability for tuberculosis drug resistance. Thus, such technological advancements by prominent players are likely to increase the availability of advanced NGS products with rapid disease detection abilities, thereby driving segment growth.
In addition, the increasing number of public-private partnerships and business expansions across various regional countries is also likely to drive the segment growth during the forecast period. For instance, in September 2024, Illumina launched its Global Capability Center in Bengaluru to enhance its technology workforce and support its international customer base. The opening of a new office and advanced genomics lab with next-generation sequencing technologies offers significant training and educational opportunities. This strategic move is expected to bolster the adoption of next-generation sequencing, driving growth in the global market.
Furthermore, the rising number of product approvals in the region will also drive segment growth during the forecast period. For instance, in October 2023, Geneseeq Technology Inc. received approval from the Chinese National Medical Products Administration (NMPA) for its lung cancer tumor mutational burden (TMS) NGS test kit. This is one of the first NGS-based TMB test kits approved in China, with a large gene panel covering 425 cancer-associated genes (GENESEEQPRIME).
Therefore, factors such as the rising number of technological advancements, increasing number of public-private partnerships, and surging number of product approvals in the region are projected to drive the segment growth during the forecast period.
China is Expected to Register a Significant Share of the Market Over the Forecast Period
Major factors driving the growth of the single-cell analysis market in China include the rising number of hospitals in the country, the high prevalence of various chronic diseases, and the surging number of product launches.
China is one of the most highly populated countries globally, accelerating the demand for healthcare services. For this reason, the number of hospitals is rapidly increasing in the country, benefiting the market studied. For instance, as per the information released by the CEIC Data in January 2023, it was observed that there were over 36,976 hospitals in China as of December 2022. This was a considerable increase from the last year, which was 36,570, a growth of over 1.11% from the previous year. The expanding healthcare infrastructure provides more avenues for adopting single-cell analysis technologies, facilitating advanced diagnostics, precision medicine, and research initiatives across a more extensive network of medical institutions. The substantial rise in hospitals reflects an expanding market potential for single-cell analysis applications in China.
Furthermore, the prominent players have been working on novel growth strategies in the country that will drive market growth during the forecast period. For instance, in June 2023, Abioscene and MobiNova introduced MobiAnalyzer, a single-cell data analysis software designed for the MobiNova-100 platform. This software results from a collaboration between Abiosciences and Mobidrop, offering comprehensive single-cell sequencing solutions from experiment execution to data analysis.
Similarly, in July 2023, Labcorp opened its new next-generation sequencing kit production facility and completed the expansion of its immunology and immunotoxicology lab in China as part of its global growth and investment strategy.
Therefore, factors such as the rising number of hospitals in the country, the high prevalence of various chronic diseases, and the surging number of product launches are set to drive the segment growth during the forecast period.
Asia Pacific Single Cell Analysis Industry Overview
The Asia Pacific single cell analysis market is moderately consolidated due to a few large companies dominating the majority of the market, including Agilent Technologies Inc., Beckman Coulter Inc. (Danaher Corporation), Becton, Dickinson, and Company, Bio-Rad Laboratories Inc., and Standard BioTools, among others.
Asia Pacific Single Cell Analysis Market Leaders
-
Agilent Technologies Inc.
-
Beckman Coulter Inc. (Danaher Corporation)
-
Becton, Dickinson, and Company
-
Bio-Rad Laboratories Inc.
-
Standard BioTools
*Disclaimer: Major Players sorted in no particular order
Asia Pacific Single Cell Analysis Market News
- September 2024: 10x Genomics, Inc. introduced the Chromium Xo, expanding its range of Chromium single-cell instruments. This new offering is tailored for researchers seeking high-quality data while operating within budget constraints. Chromium Xo provides a cost-effective solution for routine, high-performance single-cell analysis.
- August 2024: Parse Biosciences entered a strategic agreement with Taiwan-based Prisma Biotech to expand its presence in Taiwan and the broader Asia-Pacific region. This collaboration will provide greater access to Parse鈥檚 comprehensive single-cell analysis portfolio for researchers in the region, including advanced solutions such as Evercode Whole Transcriptome, Evercode TCR, Evercode BCR, and the associated data analysis platform, Trailmaker. This partnership aims to strengthen the availability of cutting-edge single-cell technologies across Asia-Pacific.
Asia Pacific Single Cell Analysis Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Technological Advancements in Single-cell Analysis Products
4.2.2 Increasing Investments in Cancer Research
4.2.3 Rising Prevalence of Chronic Diseases
4.3 Market Restraints
4.3.1 High Cost of Single Cell Analysis Instruments
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value- in USD)
5.1 By Technique
5.1.1 Flow Cytometry
5.1.2 Next Generation Sequencing
5.1.3 Polymerase Chain Reaction (PCR)
5.1.4 Microscopy
5.1.5 Mass Spectrometry
5.1.6 Other Techniques
5.2 By Application
5.2.1 Research Applications
5.2.2 Medical Applications
5.3 By End User
5.3.1 Academic and Research Laboratories
5.3.2 Biotechnology and Pharmaceutical Companies
5.3.3 Hospital and Diagnostic Laboratories
5.4 By Country
5.4.1 China
5.4.2 Japan
5.4.3 India
5.4.4 Australia
5.4.5 South Korea
5.4.6 Rest of Asia-Pacific
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Agilent Technologies Inc.
6.1.2 Beckman Coulter Inc. (Danaher Corporation)
6.1.3 Becton, Dickinson, and Company
6.1.4 Bio-Rad Laboratories Inc.
6.1.5 Standard BioTools
6.1.6 Illumina Inc.
6.1.7 Merck KGaA
6.1.8 Qiagen NV
6.1.9 Thermo Fisher Scientific Inc.
6.1.10 Takara Bio Inc.
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Asia Pacific Single Cell Analysis Industry Segmentation
As per the report's scope, single-cell analysis involves studying individual cells to uncover tissue heterogeneity, aiding in personalized medicine. The Asia Pacific single-cell analysis market, is segmented by technique, application, end user, and geography. The technique segment is further segmented into flow cytometry, next-generation sequencing, polymerase chain reaction (PCR), microscopy, mass spectrometry, and other techniques. The application segment is further bifurcated into research applications and medical applications. The end-user segment is divided into academic and research laboratories, biotechnology and pharmaceutical companies, and hospital and diagnostic laboratories. The Asia-Pacific segment is divided into China, Japan, India, Australia, South Korea, and the Rest of Asia-Pacific. The report offers the value (in USD) for the above segments.
| By Technique | |
| Flow Cytometry | |
| Next Generation Sequencing | |
| Polymerase Chain Reaction (PCR) | |
| Microscopy | |
| Mass Spectrometry | |
| Other Techniques |
| By Application | |
| Research Applications | |
| Medical Applications |
| By End User | |
| Academic and Research Laboratories | |
| Biotechnology and Pharmaceutical Companies | |
| Hospital and Diagnostic Laboratories |
| By Country | |
| China | |
| Japan | |
| India | |
| Australia | |
| South Korea | |
| Rest of Asia-Pacific |
Asia Pacific Single Cell Analysis Market Research FAQs
How big is the Asia Pacific Single Cell Analysis Market?
The Asia Pacific Single Cell Analysis Market size is expected to reach USD 0.76 billion in 2024 and grow at a CAGR of 16.80% to reach USD 1.66 billion by 2029.
What is the current Asia Pacific Single Cell Analysis Market size?
In 2024, the Asia Pacific Single Cell Analysis Market size is expected to reach USD 0.76 billion.
Who are the key players in Asia Pacific Single Cell Analysis Market?
Agilent Technologies Inc., Beckman Coulter Inc. (Danaher Corporation), Becton, Dickinson, and Company, Bio-Rad Laboratories Inc. and Standard BioTools are the major companies operating in the Asia Pacific Single Cell Analysis Market.
What years does this Asia Pacific Single Cell Analysis Market cover, and what was the market size in 2023?
In 2023, the Asia Pacific Single Cell Analysis Market size was estimated at USD 0.63 billion. The report covers the Asia Pacific Single Cell Analysis Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Asia Pacific Single Cell Analysis Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Asia Pacific Single Cell Analysis Industry Report
Statistics for the 2024 Asia Pacific Single Cell Analysis market share, size and revenue growth rate, created by 糖心vlog传媒鈩� Industry Reports. Asia Pacific Single Cell Analysis analysis includes a market forecast outlook for 2024 to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
